In a randomized double-blind study, 107 patients with extrinisic, intrinsic or mixed
bronchial asthma and impaired lung function received either
picumast dihydrochloride (3,4-dimethyl-7-[4-(4-chlorobenzyl)
piperazine-1-yl]propoxycoumarin dihydrochloride) 1 mg or placebo twice daily for 6 weeks after a 2-week placebo phase. Patients given
picumast dihydrochloride demonstrated significant improvements compared with baseline in morning and evening peak flow and asthmatic symptoms like morning tightness,
cough, dyspnoea, obstruction, number of
asthma attacks during night and day, sum of asthmatic symptom scores, in vital capacity and Tiffeneau index, and a significant reduction of inhaled adjuvant medications. In contrast, placebo recipients improved significantly only in daytime
asthma attacks, obstruction, sum of symptom scores, and Tiffeneau index. The differences between the
picumast dihydrochloride and placebo groups significantly favoured
picumast dihydrochloride for improvements in mean number of daytime
asthma attacks, morning tightness,
aerosol use and sum of symptom scores. Adverse reactions were minor and infrequent; no tiredness occurred with
picumast dihydrochloride. Tolerability of both
picumast dihydrochloride and placebo was rated as "good" to "very good" by patients and physicians.